Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Fondazione Ricerca Traslazionale
Sponsor

Fondazione Ricerca Traslazionale

Italy Via Dei Santi Quattro 61, 00184 Rome, Italy

About the sponsor

Clinical research in non-small cell lung cancer spans advanced, metastatic, and locally advanced disease, with attention to treatment selection across first-line, maintenance, and later-line settings.

  • PD-L1-positive disease
  • Stage III lung cancer
  • Relapsed and progressing disease

Research activity includes approaches aimed at improving tumour control and survival in patients with unresectable or recurrent NSCLC.

About Specializations

Fondazione Ricerca Traslazionale runs clinical trials in conditions such as Non-small cell lung cancer, Non-small cell lung cancer stage III, Non-small cell lung cancer stage IV, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

8 clinical trials

Non-small cell lung cancer

Recruiting

Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione Ricerca Traslazionale

Non-small cell lung cancer stage III

Recruiting

Study on Tislelizumab and Chemotherapy for Patients with Stage III PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fondazione Ricerca Traslazionale

Non-small cell lung cancer

Recruiting

Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MPS-102
  • Sponsor:Fondazione Ricerca Traslazionale

Non-small cell lung cancer stage IV

Recruiting

Study Comparing Atezolizumab Alone and Atezolizumab with Bevacizumab for First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Ricerca Traslazionale

Non-small cell lung cancer

Not yet recruiting

Study of amivantamab and pemetrexed for patients with non-small cell lung cancer who have EGFR exon20 insertion mutations and cannot receive platinum therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Fondazione Ricerca Traslazionale

Non-small cell lung cancer

Not yet recruiting

Study of Cabozantinib for Patients with Non-Small Cell Lung Cancer and MET Deregulation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione Ricerca Traslazionale

Non-small cell lung cancer

Not yet recruiting

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacomitinib
  • Sponsor:Fondazione Ricerca Traslazionale

Non-small cell lung cancer stage III

Not yet recruiting

Study on Durvalumab and Chemotherapy for Patients with Relapsed Stage III Non-Small Cell Lung Cancer After Chemoradiotherapy and Durvalumab Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione Ricerca Traslazionale

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.